Goldenwell Biotech, Inc.

GWLL OTC SEC CIK 1800373
Follow Goldenwell Biotech Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$36.9K −21.7% vs same quarter last year
EPS, diluted $0.00
Operating cash flow −$47.3K −179.6% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
$55
$0
$0
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$1M−$500K$0$500KFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$55−$296.5K
FY24$139−$131.5K
FY23$2.3K−$117.4K
FY22$47.8K−$985.1K
FY21$16K−$117K
FY20$0−$6.3K
FY19$0−$2.3K
FY18--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−600000%−400000%−200000%0%200000%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2521.8%−206047.3%−539038.2%
FY2446%−88559.7%−94602.9%
FY2328.5%−4949.8%−5015.4%
FY2252.7%−2060.9%−2060.9%
FY2152.5%−740.7%−732.6%
FY20---
FY19---
FY18---
Net margin vs the sectorMedian of Consumer companies filing with the SEC
  • Goldenwell Biotech
  • Consumer median
−600000%−400000%−200000%0%200000%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGoldenwell BiotechConsumer median
FY25−539038.2%0.9%
FY24−94602.9%1.3%
FY23−5015.4%1.4%
FY22−2060.9%1.6%
FY21−732.6%2.2%
FY20-0.4%
FY19-1.7%
FY18-2.6%

News

No stories filed under Goldenwell Biotech yet - coverage appears here as the news feed clusters it.